GlaxoSmithKline of Britain is near a deal to buy the biopharmaceutical company Human Genome Sciences on friendly terms for about $2.8 billion, potentially ending a long hostile takeover campaign, a person briefed on the matter said on Sunday.
Under the new terms of the deal, GlaxoSmithKline would pay about $14 a share in cash, this person said.
An agreement could be announced as soon as Monday morning, this person said, cautioning that the talks might still fall apart.
To read the full, original article click on this link: Glaxo Is Said to Be Near a Deal for Human Genome Sciences - NYTimes.com
